designer491/ Shutterstock.com
The Patent Trial and Appeal Board (PTAB) has partly accepted pharmaceutical company Lupin Limited’s petition for an inter partes review (IPR) of claims in a patent covering a compound that helps to treat HIV.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Vertex Pharmaceuticals; Lupin Limited; PTAB; HIV; inter partes review; patents; USPTO; Patent Trial and Appeal Board
